Literature DB >> 34093891

Change of Therapeutic Response Classification According to Recombinant Human Thyrotropin-Stimulated Thyroglobulin Measured at Different Time Points in Papillary Thyroid Carcinoma.

Jang Bae Moon1, Subin Jeon1, Ki Seong Park2, Su Woong Yoo1, Sae-Ryung Kang1, Sang-Geon Cho2, Jahae Kim2,3, Changho Lee1,3, Ho-Chun Song2,3, Jung-Joon Min1,3, Hee-Seung Bom1,3, Seong Young Kwon1,3.   

Abstract

PURPOSE: We investigated whether response classification after total thyroidectomy and radioactive iodine (RAI) therapy could be affected by serum levels of recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin (Tg) measured at different time points in a follow-up of patients with papillary thyroid carcinoma (PTC).
METHODS: A total of 147 PTC patients underwent serum Tg measurement for response assessment 6 to 24 months after the first RAI therapy. Serum Tg levels were measured at 24 h (D1Tg) and 48-72 h (D2-3Tg) after the 2nd injection of rhTSH. Responses were classified into three categories based on serum Tg corresponding to the excellent response (ER-Tg), indeterminate response (IR-Tg), and biochemical incomplete response (BIR-Tg). The distribution pattern of response classification based on serum Tg at different time points (D1Tg vs. D2-3Tg) was compared.
RESULTS: Serum D2-3Tg level was higher than D1Tg level (0.339 ng/mL vs. 0.239 ng/mL, P < 0.001). The distribution of response categories was not significantly different between D1Tg-based and D2-3Tg-based classification. However, 8 of 103 (7.8%) patients and 3 of 40 (7.5%) patients initially categorized as ER-Tg and IR-Tg based on D1Tg, respectively, were reclassified to IR-Tg and BIR-Tg based on D2-3Tg, respectively. The optimal cutoff values of D1Tg for the change of response categories were 0.557 ng/mL (from ER-Tg to IR-Tg) and 6.845 ng/mL (from IR-Tg to BIR-Tg).
CONCLUSION: D1Tg measurement was sufficient to assess the therapeutic response in most patients with low level of D1Tg. Nevertheless, D2-3Tg measurement was still necessary in the patients with D1Tg higher than a certain level as response classification based on D2-3Tg could change. © Korean Society of Nuclear Medicine 2021.

Entities:  

Keywords:  Papillary thyroid carcinoma; Radioactive iodine; Recombinant human thyrotropin; Response classification; Thyroglobulin

Year:  2021        PMID: 34093891      PMCID: PMC8139997          DOI: 10.1007/s13139-021-00699-2

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  17 in total

1.  Serial measurements of serum thyroglobulin in response to recombinant human thyrotropin stimulation.

Authors:  Richard Weiss; James Magner
Journal:  Thyroid       Date:  2015-04-29       Impact factor: 6.568

2.  Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.

Authors:  Tae Yong Kim; Won Bae Kim; Eun Sook Kim; Jin Sook Ryu; Jeong Seok Yeo; Seong Chul Kim; Suck Joon Hong; Young Kee Shong
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

3.  Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy.

Authors:  K H Dow; B R Ferrell; C Anello
Journal:  Thyroid       Date:  1997-08       Impact factor: 6.568

4.  Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy.

Authors:  Fernanda Vaisman; Denise Momesso; Daniel A Bulzico; Cencita H C N Pessoa; Fernando Dias; Rossana Corbo; Mário Vaisman; R Michael Tuttle
Journal:  Clin Endocrinol (Oxf)       Date:  2012-07       Impact factor: 3.478

Review 5.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

6.  Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.

Authors:  F Pacini; E Molinaro; F Lippi; M G Castagna; L Agate; C Ceccarelli; D Taddei; R Elisei; M Capezzone; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

Review 7.  MANAGEMENT OF ENDOCRINE DISEASE: The role of rhTSH in the management of differentiated thyroid cancer: pros and cons.

Authors:  Luca Giovanella; Leonidas H Duntas
Journal:  Eur J Endocrinol       Date:  2019-10       Impact factor: 6.664

8.  Estimation of true serum thyroglobulin concentration using simultaneous measurement of serum antithyroglobulin antibody.

Authors:  Byeong-Cheol Ahn; Won Kee Lee; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee
Journal:  Int J Endocrinol       Date:  2013-03-31       Impact factor: 3.257

Review 9.  Recombinant human thyrotropin (rhTSH) in the follow-up and treatment of patients with thyroid cancer.

Authors:  Emilio Bombardieri; Ettore Seregni; Carlo Villano; Gianluca Aliberti; Franco Mattavelli
Journal:  Tumori       Date:  2003 Sep-Oct

10.  Optimization of serum thyroglobulin measured at different time points for prognostic evaluation in differentiated thyroid carcinoma patients.

Authors:  Pupree Mutsuddy; Subin Jeon; Su Woong Yoo; Yingjie Zhang; Md Sunny Anam Chowdhury; Jahae Kim; Ho-Chun Song; Hee-Seung Bom; Jung-Joon Min; Seong Young Kwon
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.